Abstracts tagged "Autoantibody(ies)"

Abstract Number: 2052 • ACR Convergence 2025
Prevalence of anti-neutrophil extracellular trap antibodies and their relationship with the clinical characteristics of patients with idiopathic inflammatory myopathies.
Agustin Hernández-López¹, Nancy R Mejía Domínguez², Yatzil Reyna Juárez³, María José Ostos Prado⁴, Beatriz Alcalá Carmona⁵, Jennifer Tiaré Balderas Miranda⁶, Carlos A. Núñez-Álvarez⁵, Marta E. Baños-Laredo⁷, Álvaro Abiel Sierra-Salazar⁵, Johan Camacho-Pérez⁵, Marco Aurelio Martínez-Rivera⁵, Diana Gómez-Martín⁸ and Jiram Torres-Ruiz⁹, ¹Instituo Nacional de Ciencias Médicas y Nutricion Salvador Zubirán, Morelia, Michoacan de Ocampo, Mexico, ²Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, ³Instituto Politècnico Nacional, Tultitlán de Mariano Escobedo, Mexico State, Mexico, ⁴Instituto Nacional De Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ⁵INCMNSZ, Cdmx, Distrito Federal, Mexico, ⁶Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, ⁷INCMNSZ, Cdmx, Mexico, ⁸INCMNSZ, Mexico city, Federal District, Mexico, ⁹INCMNSZ, Ciudad de México, Mexico
Background/Purpose: Patients with idiopathic inflammatory myopathies (IIM) have increased production and decreased clearance of neutrophil extracellular traps (NETs), which may promote the production of anti-NETs…
Abstract Number: 1559 • ACR Convergence 2025
Anti-Cytolethal Distending Toxin Antibodies in Systemic Sclerosis: Associations with Gastrointestinal Disease and Immune Dysregulation
Francesca Romana Di Ciommo¹, Livia Casciola-Rosen², Ashish Balar³, Ami Shah⁴, Michael Hughes⁵, Walter Morales⁶, Mark Pimentel⁷, Brittany L Adler⁸ and Zsuzsanna McMahan⁹, ¹La Sapienza University of Rome, Rome, Italy, ²Johns Hopkins University, Baltimore, MD, ³UTHealth Houston, Houston, TX, ⁴Johns Hopkins Rheumatology, Baltimore, MD, ⁵Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, ⁶Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Karsh Division of Gastroenterology and MAST Program, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Johns Hopkins University School of Medicine, Baltimore, MD, ⁹UT Health Houston, Houston, TX
Background/Purpose: Anti- Cytolethal Distending Toxin (CDT) antibodies may serve as biomarkers for post-infectious autoimmunity and aid in clinical risk stratification. In this study, we aimed…
Abstract Number: 0983 • ACR Convergence 2025
Detecting Autoreactive CD4+ T Cells Relevant to Mixed Connective Tissue Disease
Grace Frechette, Thamotharampillai Dileepan, Marc Jenkins and Shawn Mahmud, University of Minnesota, Minneapolis
Background/Purpose: Mixed connective tissue disease (MCTD) is a systemic autoimmune disorder marked by a U1-small nuclear ribonucleoprotein (U1-snRNP) autoantibody. The majority of U1-snRNP antibodies in…
Abstract Number: 0603 • ACR Convergence 2025
Transverse Myelitis in Systemic Lupus Erythematosus: Disease Manifestations and Clinical Outcomes from Multi-Center Data
Amir Daneshvar¹, Areeb Tiwana², Dana Nachawati¹, Keri Ann Pfeil¹, Elleson Harper¹, Lindsay Frumker³, Meghan Gump¹ and Omer Pamuk⁴, ¹University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ²Canton Medical Education Foundation, Canton, OH, ³University hospitals Cleveland medical center, Highland Heights, OH, ⁴University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with widespread clinical manifestations. Neuropsychiatric SLE (NPSLE), a complex and poorly understood subset of SLE,…
Abstract Number: 0300 • ACR Convergence 2025
Exploring Malignancy in Anti-synthetase Syndrome: A Multisite Retrospective Study
Reena Yaman¹, Archit Srivastava², Alejandro Arango Martinez³, Caroyln Harvey⁴, Ronald Butendieck⁵, Vikas Majithia⁶ and Florentina Berianu¹, ¹Mayo Clinic Florida, Jacksonville, FL, ²Mayo Clinic, Florida, Jacksonville, FL, ³Universidad Pontificia Bolivariana, Medellín, Colombia, ⁴Mayo Clinic, Phoenix, AZ, ⁵Mayo Clinic Florida, Jacksonville, ⁶Mayo Clinic Hospital, Jacksonville, FL
Background/Purpose: Anti-synthetase syndrome (ASyS) is a rare, heterogeneous inflammatory myopathy characterized by presence of anti-aminoacyl transfer RNA synthetase autoantibodies with multisystem disease manifestations including myositis,…
Abstract Number: 0012 • ACR Convergence 2025
KT501, a CD19/BCMA/CD3 trispecific antibody, leads to rapid and deep B-cell depletion with well-tolerated safety
Min Bao, John Wang, Jay Zhao and Weihao Xu, Kali Therapeutics, San Mateo, CA
Background/Purpose: Chimeric antigen receptor T-cell (CAR-T) therapies targeting CD19 or B-cell maturation antigen (BCMA) have shown unprecedented effects in treatment-resistant autoimmune diseases such as systemic…
Abstract Number: 2665 • ACR Convergence 2025
Preexisting Antibodies Against Vaccine Antigens Are Preserved In Patients With Systemic Lupus Erythematosus and Sjögren’s Disease Upon Ianalumab Treatment While Autoantibodies Decline
Thomas Dörner¹, Nan Shen², Thomas Grader-Beck³, Caroline Walter⁴, Catherine Wioland⁴, Celine Rauld⁴, Patrick Schmutz⁴, Simone Riek⁴, Wolfgang Hueber⁵, CAROLE SIPS⁶, Stephen Oliver⁴, Carol Lau⁷, Claire Bonal⁶ and Isabelle Isnardi⁸, ¹Charite Universitétsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany, ²Shanghai Jiang Tong University School of Medicine, Shanghai, China (People's Republic), ³Johns Hopkins, Reisterstown, MD, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharmaceuticals, Basel, Switzerland, ⁶Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, ⁸Novartis, Gueberschwihr, France
Background/Purpose: Ianalumab, an afucosylated mAb, depletes B cells via enhanced antibody (Ab)-dependent cellular cytotoxicity and blocks B cell-activating factor (BAFF): BAFF-receptor (BAFF-R) mediated signals.1 It…
Abstract Number: 2417 • ACR Convergence 2025
Anti-dense fine speckled 70 antibodies in undefined disease, systemic autoimmune rheumatic diseases and controls
Rammohan Mylavarapu¹, Meghna Gavali², Bansi Kashyap Parijeya³, Kaushik Puranam⁴ and Liza rajasekhar⁵, ¹NIZAMS INSTITUTE OF MEDICAL SCIENCES, Hyderabad, Telangana, India, ²nizam's institute of medical sciences ,Hyderabad, Hyderabad, Telangana, India, ³Synergy superspeciality hospital, Rajkot, Gujarat, India, ⁴Nizams Institute Of Medical Sciences , Hyderabad, hyderabad, Telangana, India, ⁵Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
Background/Purpose: Systemic autoimmune rheumatic diseases (SARD) are a heterogeneous group of disorders marked by the presence of antinuclear antibodies (ANA), commonly detected by HEp-2 cell-based…
Abstract Number: 2034 • ACR Convergence 2025
Hidden Burden in Rheumatology: Cross-Sectional Study of Hearing Loss in Systemic Autoimmune Diseases
Ruddy Paola Montoya Rumpf¹, Liliam María Murcia Munévar¹, Jairo Cajamarca-Baron², Dominique Daniela González Casas¹, María Fernanda González Sánchez¹, Adriana Rojas-Villarraga³, Henry Leonardo Martínez Bejarano¹, Adriana Isaza¹, Alejandro Escobar¹, Maria Camila Restrepo Guarnizo¹, Nicolás Santiago Rodríguez¹ and Claudia Ibáñez-Antequera¹, ¹Fundacion universitaria de ciencias de la salud, bogota, Distrito Capital de Bogota, Colombia, ²Fundacion universitaria de ciencia de la Salud, Bogota, Distrito Capital de Bogota, Colombia, ³Fundacion Universitaria de Ciencias de la salud, Bogotá, Distrito Capital de Bogota, Colombia
Background/Purpose: Autoimmune inner ear disease is a progressive sensorineural hearing loss of autoimmune origin, often underdiagnosed due to the lack of specific criteria, and requires…
Abstract Number: 1524 • ACR Convergence 2025
Hydroxychloroquine Reduces Autoantibody Levels in Persons at Risk for Systemic Lupus Erythematosus
David Karp¹, Prithvi Raj¹, Changsong Zhu¹, Dajiang Liu², Duanping Liao² and Nancy Olsen³, ¹UT Southwestern Medical Center, Dallas, TX, ²Penn State College of Medicine, Hershey, PA, ³Penn State University/Milton S Hershey, Hershey, PA
Background/Purpose: The Study of Antimalarials in Incomplete Lupus Erythematosus (SMILE, NCT03030118) was a double-blind, randomized, placebo-controlled study of hydroxychloroquine (HCQ) to prevent the development of…
Abstract Number: 0960 • ACR Convergence 2025
Pharmaceutical Blockade of the Neonatal Fc Gamma Receptor Ameliorates Autoimmunity, Inflammation and Fibrosis in the Topoisomerase I Mouse Model of Systemic Sclerosis
Cuong Tran-Manh¹, Thuong Trinh-Minh², Christoph Liebel³, Bas van der Woning⁴, Piotr Zabrocki⁵ and Jörg Distler⁶, ¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Nordrhein-Westfalen, Germany, ²Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ³Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁴argenx BV, Boston, MA, ⁵argenx, Ghent, Belgium, ⁶University Hospital Duesseldorf and HHU, Duesseldorf, Germany
Background/Purpose: SSc is a rare, chronic, systemic autoimmune rheumatic disease characterized by progressive skin and internal organ fibrosis, severe vasculopathy and immune dysregulation with production…
Abstract Number: 0862 • ACR Convergence 2025
In immune-mediated necrotising myopathy, anti-HMGCR antibodies inhibit HMGCR activity, leading to the sarcoplasmic accumulation of lipid droplets and myofibres necrosis
Margherita Giannini¹, Giulia Quiring², Mustapha Oulad-Abdelghani³, Béatrice Lannes¹, Yves Allenbach⁴, Olivier Benveniste⁵, Olivier Boyer⁶, Aleksandra Nadaj Pakleza¹, Bernard Geny⁷ and Alain Meyer⁸, ¹Strasbourg University Hospital, Strasbourg, France, ²University of Strasbourg, Strasbourg, France, ³IGBMC, Strasbourg, France, ⁴SORBONNE UNIVERSITE, Paris, France, ⁵Sorbonne Uniersite, Hopital de la Pitie-Salpetriere, Paris, France, ⁶University of Rouen, Rouen, France, ⁷UR ³⁰⁷², Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg; FranceExplorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg;, Strasbourg, Alsace, France, ⁸Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Explorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, UR ³⁰⁷², Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg; France, Strasbourg, Alsace, France
Background/Purpose: The aim of this study was to investigate whether in immune-mediated necrotising myopathy (IMNM), anti-HMGCR antibodies interfere with HMGCR activity and have a myopathic…
Abstract Number: 0299 • ACR Convergence 2025
Interpreting Myositis Autoantibody Line-Blot Immunoassays in Real-World Settings: Implications for Diagnostic Accuracy for Inflammatory Myopathies
pei-Hsinq lai¹, TING-YUAN LAN², Chiao-Feng Cheng³, Tai-Ju Lee⁴, Ting-Wei Chang⁵, Jui-Hung Kao⁶, Kuan-Yen Lin⁷, Cheng-Hsun Lu⁸, Chiehyu Shen⁹, Ko-Jen Li⁸ and Song-Chou Hsieh¹⁰, ¹Taipei City Hospital, Taichung, Taiwan, ²National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan, ³National Taiwan University Hospital, Taipei City, Taiwan (Republic of China), ⁴National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan (Republic of China), ⁵National Taiwan University Hospital Hsinchu Branch, Taichung, Taiwan, ⁶Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, Taipei, Taiwan (Republic of China), ⁷National Taiwan University Hospital, Hsin-Chu Branch, Hsin-Chu City, Taiwan (Republic of China), ⁸National Taiwan University Hospital, Taipei, Taiwan, ⁹National Taiwan University Hospital, Taipei city, Taiwan, ¹⁰National Taiwan Unuversity Hospital, Taipei City, Taiwan (Republic of China)
Background/Purpose: Idiopathic inflammatory myopathies (IIM) present with diverse clinical features and disease courses. The myositis autoantibody line blot immunoassay (LIA) has advanced IIM diagnostics and…
Abstract Number: 0011 • ACR Convergence 2025
KT502, a novel CD19-directed TCE (T-cell engager), leads to rapid and deep B-cell depletion with low cytokine release
Min Bao, John Wang, Jay Zhao and Weihao Xu, Kali Therapeutics, San Mateo, CA
Background/Purpose: Chimeric antigen receptor T-cell (CAR-T) therapies targeting CD19 have shown unprecedented effects in treatment-resistant autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis…
Abstract Number: 2652 • ACR Convergence 2025
Anti-mitochondrial antibodies in systemic sclerosis target enteric neurons and are associated with GI dysmotility
Zsuzsanna McMahan¹, Srinivas Puttapaka², Livia Casciola-Rosen³, Timothy Kaniecki³, Laura Gutierrez³, Su Hong MIng², Philippa Seika² and Subhash Kulkarni⁴, ¹UT Health Houston, Houston, TX, ²BIDMC/Harvard, Boston, MA, ³Johns Hopkins University, Baltimore, MD, ⁴BIDMC, Boston, MA
Background/Purpose: Most patients with systemic sclerosis (SSc) experience gastrointestinal (GI) dysmotility. The enteric nervous system (ENS) regulates GI motility, and its dysfunction causes dysmotility. A…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].